UBS Group reaffirmed their neutral rating on shares of Shire (LON:SHP) in a research report sent to investors on Tuesday, investing.thisismoney.co.uk reports.

Several other brokerages have also recently weighed in on SHP. Barclays reiterated an equal weight rating on shares of Shire in a research note on Friday, October 19th. Deutsche Bank reiterated a buy rating on shares of Shire in a research note on Friday, October 12th. Berenberg Bank cut shares of Shire to a hold rating and lifted their price target for the stock from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a research note on Thursday, September 6th. Finally, Credit Suisse Group reiterated an outperform rating on shares of Shire in a research note on Thursday, November 1st. Seven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of GBX 4,725.30 ($61.74).

Shares of SHP stock opened at GBX 4,563 ($59.62) on Tuesday. Shire has a 12-month low of GBX 2,940.50 ($38.42) and a 12-month high of GBX 5,021 ($65.61).

About Shire

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Featured Article: Intrinsic Value and Stock Selection

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.